Advertisement
Canada markets close in 3 hours 24 minutes
  • S&P/TSX

    22,028.72
    +156.76 (+0.72%)
     
  • S&P 500

    5,068.90
    +58.30 (+1.16%)
     
  • DOW

    38,479.66
    +239.68 (+0.63%)
     
  • CAD/USD

    0.7316
    +0.0015 (+0.20%)
     
  • CRUDE OIL

    82.93
    +1.03 (+1.26%)
     
  • Bitcoin CAD

    91,058.88
    +626.44 (+0.69%)
     
  • CMC Crypto 200

    1,436.62
    +21.86 (+1.55%)
     
  • GOLD FUTURES

    2,338.50
    -7.90 (-0.34%)
     
  • RUSSELL 2000

    2,001.27
    +33.80 (+1.72%)
     
  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     
  • NASDAQ

    15,688.14
    +236.83 (+1.53%)
     
  • VOLATILITY

    16.30
    -0.64 (-3.78%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6833
    -0.0017 (-0.25%)
     

Boasting A 69% Return On Equity, Is AbbVie Inc. (NYSE:ABBV) A Top Quality Stock?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we'll use ROE to better understand AbbVie Inc. (NYSE:ABBV).

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

Check out our latest analysis for AbbVie

How To Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

ADVERTISEMENT

So, based on the above formula, the ROE for AbbVie is:

69% = US$12b ÷ US$17b (Based on the trailing twelve months to December 2022).

The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.69 in profit.

Does AbbVie Have A Good ROE?

By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. As you can see in the graphic below, AbbVie has a higher ROE than the average (24%) in the Biotechs industry.

roe
roe

That's what we like to see. With that said, a high ROE doesn't always indicate high profitability. Especially when a firm uses high levels of debt to finance its debt which may boost its ROE but the high leverage puts the company at risk. Our risks dashboardshould have the 3 risks we have identified for AbbVie.

The Importance Of Debt To Return On Equity

Most companies need money -- from somewhere -- to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the use of debt will improve the returns, but will not change the equity. That will make the ROE look better than if no debt was used.

AbbVie's Debt And Its 69% ROE

It seems that AbbVie uses a huge volume of debt to fund the business, since it has an extremely high debt to equity ratio of 3.68. So although the company has an impressive ROE, the company might not have been able to achieve this without the significant use of debt.

Summary

Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. In our books, the highest quality companies have high return on equity, despite low debt. If two companies have the same ROE, then I would generally prefer the one with less debt.

Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So I think it may be worth checking this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here